Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

World Journal of Urology

Volumn 22, Issue 1, 2004, Pages 67-71

  Forbes, Katie ^a   Gillette, Karin ^a   Kelley, Laura A ^a   Sehgal, Inder ^b  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Motility; Prostate cancer; Secondary metastasis; Urokinase plasminogen activator receptor

Indexed keywords

CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR 2; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; SOMATOMEDIN C; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL; ARTICLE; CELL DIVISION; CELL MOTION; DRUG EFFECT; ENZYMOLOGY; MALE; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; FIBROBLAST GROWTH FACTOR 2; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATORS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; URINARY PLASMINOGEN ACTIVATOR;

EID: 4344656472     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00345-003-0395-3     Document Type: Article

References (20)

1. Berger D (2002) Plasmin/plasminogen system in colorectal cancer. World J Surg 26:767-771
2. Biliran H, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61:8676-8682
3. Bissell MJ, Le Beyec J, Anderson RL (2002) Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases. J Natl Cancer Inst 94:4-5
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-83
5. Delworth MG, Nishioka K, Pettaway CA, Gutman M, Killion JJ, Von Eschenbach AC, Fidler IJ (1995) Systemic administration of 4-amidinoindanon-1- (2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol 6:293-299
6. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57:3594-3599
7. Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16:513-528
8. Greene GF, Kitadal Y, Pettaway CA, Von Eschenbach AC, Bucana CD, Fidler IJ (1997) Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571-1582
9. Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D (1992) Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombo Haemost 68:662-666
10. Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420:79-85
11. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39:123-129
12. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627-1636
13. Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390-23970
14. Rabbani SA, Xing RH (1998) Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12:911-2
15. Sehgal I, Forbes K, Webb M (2003) Reduced expression of MMPs, plasminogen activators and TIMPS in prostate cancer cells during repeated metastatic selection. Anticancer Res 23: (in press)
16. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, Von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-81
17. Thompson TC, Timme TL, Sehgal I (1998) Oncogenes, growth factors, and hormones in prostate cancer. In: Dickson RB, Salomon DS (eds) Hormones and growth factors in development and neoplasia. Wiley-Liss, New York, pp 327-359
18. Varkarakis MJ, Winterberger AR, Gaeta J, Moore RH, Murphy GP (1974) Lung metastases in prostate carcinoma. Urology 3:447-452
19. Von Bokhoven A, Garcia MV, Korch C, Miller, GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res61:6340-6344
20. Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349